Australian Fees To Rise As Registrations Decline
The Therapeutic Goods Administration says that its cost-recovery fees need to go up, mainly because of a fall in the number of products on the therapeutic products register. It is also seeing a rise in the cost of the fee-free services it provides.
You may also be interested in...
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation.
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.